August 25, 2010
Bioniche & University of Ottawa Sign Exclusive Global License Agreement for Natural Health Technology

August 20, 2010
Additional Phase III Clinical Trial with UrocidinTM Expected to Commence in 2010

Check latest
stock price

All prices delayed at least 15 minutes.
Source: TSX Inc.

Corporate News Release

Bioniche Recognized as One of the Top 10 Life Science Companies in Canada

04/12/07

BELLEVILLE, ON, December 4, 2007 – Bioniche Life Sciences Inc. (TSX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, today announced that it has been recognized as one of Canada’s Top 10 Life Sciences Companies for 2008. Bioniche was chosen by a group of distinguished venture capital investors based on the Company’s attractiveness as an exceptional investment in Canada.

“We are honoured to have received this award,” said Mr. Graeme McRae, President & CEO of Bioniche Life Sciences Inc. “It recognizes the significant achievements made by our company in the last year, including the initiation of our Phase III clinical trial with our proprietary Mycobacterial Cell Wall-DNA Complex (MCC) in human bladder cancer and the authorization of our E. coli O157:H7 food safety cattle vaccine for Canadian distribution, followed by preliminary sales of this important food safety product.” Winners of the Top 10 Competition are chosen by an independent expert panel of Canadian and U.S. venture capitalists. Originally developed to promote the 10 most promising life science companies from across Canada to Canadian and international investors and partners, the competition has now expanded to showcase Canada’s cleantech and technology sectors. Winning companies, working in partnership with Canadian Consulates in Boston, New York City, San Diego and San Francisco, participate in targeted investment forums in each city, providing them with an opportunity to meet with venture capital investors who have expressed an active interest in financing these companies.

In March of this year, Bioniche was recognized with a Genesis Award from the Québec biotechnology, health technology and life science industry. The “Transfer-Emergence” award was presented to the Company as part of the BIOMEDEX 2007 convention-exhibition.

In September, the Company’s E. coli O157:H7 cattle vaccine was recognized internationally as the best new veterinary product for livestock as part of the Animal Pharm Industry Excellence Awards ’07. The “best new veterinary product for livestock” award recognizes excellence in pharmaceutical or vaccine development for production animals. In this category, the 12-member panel of independent industry judges looked for the product that represented the greatest therapeutic, prophylactic, or production advance.

Back

Categories:
All Releases
Archived Releases
Animal Health
Corporate
Financial
Food Safety
Human Health